Lantern Pharma (LTRN) Net Cash Flow (2019 - 2026)
Lantern Pharma's (LTRN) quarterly Net Cash Flow came in at $477373.0 in Q1 2026, up 142.01% YoY from $197251.8 in Q1 2025, and up 112.03% on a QoQ basis from -$4.0 million in Q4 2025.
Lantern Pharma (LTRN) Net Cash Flow (2019 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 8 years of Net Cash Flow data on file, last reported at $477373.0 in Q1 2026.
- Quarterly Net Cash Flow rose 142.01% year-over-year to $477373.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.5 million (up 79.24% YoY) and the FY2025 annual result came in at -$3.1 million, up 78.29% from the prior year.
- Net Cash Flow improved to $477373.0 in Q1 2026, from -$4.0 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $1.4 million in Q3 2025 to a low of -$5.4 million in Q2 2024.
- A 5-year average of -$2.8 million and a median of -$3.4 million in 2023 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2025 — Net Cash Flow sank 656.79% — and 2026, when it jumped 142.01%.
- Tracing LTRN's Net Cash Flow over 5 years: stood at -$2.1 million in 2022, then plunged by 51.46% to -$3.1 million in 2023, then surged by 83.24% to -$524533.0 in 2024, then slumped by 656.79% to -$4.0 million in 2025, then surged by 112.03% to $477373.0 in 2026.
- The last three Net Cash Flow figures came in at $477373.0 (Q1 2026), -$4.0 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Lantern Pharma | 26.11 Mn | 26.11 Mn | - | 477,373.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 477,373.00 |
| Mar 31, 2026 | 477,373.00 |
| Dec 31, 2025 | -3.97 Mn |
| Dec 31, 2025 | -3.97 Mn |
| Sep 30, 2025 | 1.36 Mn |
| Sep 30, 2025 | 1.36 Mn |
| Jun 30, 2025 | -344,119.00 |
| Jun 30, 2025 | -344,119.00 |
| Mar 31, 2025 | -1.14 Mn |
| Mar 31, 2025 | -1.14 Mn |
| Dec 31, 2024 | -524,533.00 |
| Dec 31, 2024 | -524,533.00 |
| Sep 30, 2024 | -4.89 Mn |
| Sep 30, 2024 | -4.89 Mn |
| Jun 30, 2024 | -5.39 Mn |
| Jun 30, 2024 | -5.39 Mn |
| Mar 31, 2024 | -3.57 Mn |
| Mar 31, 2024 | -3.57 Mn |
| Dec 31, 2023 | -3.13 Mn |
| Dec 31, 2023 | -3.13 Mn |